$25.66
0.07[0.27%]
At close: May 2
$25.66
0[0.00%]
After Hours: 5:40PM EDT
Latest News for Insmed Stock (NASDAQ:INSM)
Insmed Stock (NASDAQ: INSM)
Categories: All
Tuesday, April 23, 2024
Thursday, April 11, 2024
Thursday, April 04, 2024
Monday, April 01, 2024
Wednesday, March 27, 2024
Monday, March 11, 2024
Tuesday, February 27, 2024
Thursday, February 22, 2024
Thursday, February 15, 2024
Monday, January 08, 2024
Monday, November 20, 2023
Friday, October 27, 2023
Thursday, October 26, 2023
Thursday, September 21, 2023
Tuesday, September 19, 2023
Thursday, September 07, 2023
Wednesday, September 06, 2023
Tuesday, September 05, 2023
- Why America's Car-Mart Are Trading Lower By 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Sep 5, 2023, 1:34PM
- Guggenheim Reiterates Buy on Insmed, Raises Price Target to $52Benzinga Newsdesk - Sep 5, 2023, 12:53PM
- Watching Insmed; Guggenheim Out With Note Saying "Not Very Messy After All; ARISE Delivers Clean Win In 1L MAC; Increase PT To $52, Reiterate Buy Rating; We Continue To See INSM As Best Idea"Happy Mohamed - Sep 5, 2023, 12:44PM
- Why Lung Disease Focused Stock Insmed Is Trading Higher Today?Vandana Singh - Sep 5, 2023, 12:34PM
- Brady, Airbnb, Insmed And Other Big Stocks Moving Higher On TuesdayLisa Levin - Sep 5, 2023, 10:43AM
- Insmed shares are trading higher after the company released topline results from its Phase 3 ARISE study of ARIKAYCE for nontuberculous mycobacterial lung infection caused by Mycobacterium avium complex who had not started antibiotics.Benzinga Newsdesk - Sep 5, 2023, 10:26AM
- Insmed's Phase 3 ARISE Study Of Arikayce For Nontuberculous Mycobacterial Lung Infection Met Its Primary Objective Of Demonstrating That The Quality Of Life – Bronchiectasis Respiratory Domain Works Effectively As A Patient-reported Outcome InstrumentBenzinga Newsdesk - Sep 5, 2023, 7:03AM
Friday, August 04, 2023
Thursday, August 03, 2023
Wednesday, July 26, 2023
Tuesday, May 09, 2023
Thursday, May 04, 2023
- Insmed: Q1 Earnings InsightsBenzinga Insights - May 4, 2023, 7:55AM
- Insmed Reiterates Global ARIKAYCE Revenue Outlook $285M - $300MBenzinga Newsdesk - May 4, 2023, 7:38AM
- Insmed Q1 EPS $(1.17) Misses $(1.11) Estimate, Sales $65.21M Beat $64.51M EstimateBenzinga Newsdesk - May 4, 2023, 7:37AM
- Earnings Scheduled For May 4, 2023Benzinga Insights - May 4, 2023, 6:34AM